LPL Financial LLC Buys Shares of 12,700 Nyxoah S.A. (NASDAQ:NYXH)

LPL Financial LLC purchased a new position in Nyxoah S.A. (NASDAQ:NYXH) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 12,700 shares of the company’s stock, valued at approximately $102,000.

Separately, Kovack Advisors Inc. raised its holdings in Nyxoah by 100.0% in the 4th quarter. Kovack Advisors Inc. now owns 20,000 shares of the company’s stock valued at $160,000 after acquiring an additional 10,000 shares during the last quarter.

Nyxoah Stock Performance

Shares of NYXH opened at $6.14 on Thursday. The company has a market capitalization of $209.13 million, a PE ratio of -3.28 and a beta of 1.55. The company’s fifty day moving average price is $8.13 and its 200 day moving average price is $8.88. Nyxoah S.A. has a one year low of $5.55 and a one year high of $12.21. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.28 and a quick ratio of 4.95.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03). Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. The business had revenue of $1.35 million for the quarter, compared to the consensus estimate of $2.02 million. As a group, analysts expect that Nyxoah S.A. will post -1.91 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NYXH has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Nyxoah in a research note on Tuesday, April 8th. Stifel Nicolaus dropped their target price on shares of Nyxoah from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, April 21st.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.